Skip to main content

Table 4 Multivariate stepwise regression analyses of data from 147 patients with axial spondyloarthritis followed over 2 years assessing the associations between treatment and development of erosion or fat metaplasia

From: Tumor necrosis factor inhibitor therapy but not standard therapy is associated with resolution of erosion in the sacroiliac joints of patients with axial spondyloarthritis

 

β coefficient

SE

t value

P value

TNFα inhibitor treatment

−1.33

0.47

−3.0

0.003

2 year change in SPARCC SIJ inflammation score

0.09

0.036

2.57

0.012

Baseline SSS erosion score

−0.40

0.059

−7.1

<0.0001

  1. Dependent variable: 2-year change in SSS for erosion. Adjusted R2 = 0.45. Variables not included in the model: age, sex, symptom duration, baseline Ankylosing Spondylitis Disease Activity Score, baseline SPARCC SIJ inflammation score, and baseline SSS for ankylosis. SE, standard error; SIJ, sacroiliac joint; SPARCC, Spondyloarthritis Research Consortium of Canada; SSS, Sacroiliac Joint Structural Score; TNFα, tumor necrosis factor alpha.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us